BACKGROUND: Human papillomavirus (HPV) tumor status and surgical salvage are associated with improved prognosis for patients with recurrent oropharyngeal squamous cell carcinoma (OPSCC). Current data regarding types of surgery and the impact of surgery for patients with distant metastatic disease are limited. METHODS: A retrospective analysis of patients with recurrent OPSCC from 2 institutions between 2000 and 2012 was performed. p16 immunohistochemistry and/or in situ hybridization, as clinically available, were used to determine HPV tumor status. Clinical characteristics, distribution of recurrence site, and treatment modalities were compared by HPV tumor status. Overall survival (OS) was examined using Kaplan-Meier and Cox proportional hazards methods. RESULTS: The current study included 108 patients with 65 locoregional and 43 distant metastatic first recurrences. The majority of patients were HPV-positive (80 patients). HPV-positive tumor status was associated with longer time to disease recurrence (P<.01). 
INTRODUCTION
Human papillomavirus (HPV) is responsible for a growing subset of oropharyngeal squamous cell carcinomas (OPSCCs) in the United States and abroad. [1] [2] [3] At the time of the primary diagnosis, HPV-positive tumor status is associated with improved response to chemoradiation, progression-free survival, and overall survival (OS). 4, 5 Despite improved prognosis, locoregional and distant metastatic recurrences still pose a significant disease burden. Within 3 years of diagnosis, approximately 24% to 27% of patients with HPV-positive OPSCC experience disease recurrence. 5, 6 Although the unique clinical features of HPV-positive OPSCC have been well characterized, few studies have addressed the clinical implications of recurrent disease. 7 Earlier reports have suggested unusual clinical presentations for HPV-associated recurrences. [8] [9] [10] [11] Recent prospective data from Radiation Therapy Oncology Group 0129 and 0522 trials demonstrated that site distribution and time to disease recurrence does not differ by HPV tumor status. 12 Importantly, HPV-positive tumor status [12] [13] [14] and receipt of surgical salvage 12 have been shown to be independent markers of improved prognosis among patients with recurrent OPSCC. Although type of disease recurrence (locoregional or distant) was accounted for in the Radiation Therapy Oncology Group analysis, few patients (5 patients) received surgical salvage for distant metastatic disease and details concerning salvage therapies were limited. 12 The study populations in the Erbitux in First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer (EXTREME) and Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer (SPECTRUM) trials were restricted to patients who were ineligible for surgical or radiation salvage. [13] [14] [15] Therefore, we evaluated both surgical and nonsurgical salvage therapies for patients with recurrent locoregional and distant metastatic OPSCC and their prognostic role within the context of HPV tumor status.
MATERIALS AND METHODS

Study Population
The current study was an Institutional Review Boardapproved retrospective study of patients treated at Johns Hopkins Hospital and the Greater Baltimore Medical Center between 2000 and 2012. Patients diagnosed with recurrent OPSCC or head and neck squamous cell carcinoma of unknown primary and who had known HPV tumor status were eligible. Unknown primaries were included because these tumors are frequently HPV-related. 16 Disease recurrence was defined as the diagnosis of local, regional, and/or distant disease after the completion of primary treatment with curative intent and a posttreatment disease-free interval of at least 3 months. Patients with second primary tumors or persistent disease (without a disease-free interval) were excluded.
HPV Tumor Status
HPV tumor status was based upon HPV in situ hybridization (105 patients) or p16 immunohistochemistry (94 patients), an established surrogate marker for HPV in OPSCC, 17 at the time of primary diagnosis. HPV tumor status for recurrent lesions was reported based on p16 immunohistochemistry (44 patients) or in situ hybridization (43 patients), as clinically available. Recurrent tumors with discordant HPV tumor status were excluded as second primary tumors (2 patients). 18, 19 Clinical Data Clinical data were obtained by medical record abstraction. Variables of interest at the time of the primary diagnosis were age, sex, race, history of tobacco and/or alcohol use, TNM stage of disease, and treatment. At the time of first disease recurrence, location of the recurrence (locoregional and/or distant), single or multiple sites of recurrence, anatomic site of distant metastasis, diagnostic method, treatment, and survival data were obtained. Surgical salvage data included surgical procedure, surgical margin status, and length of hospitalization. Surgical margin status was based on the final pathology report. Close surgical margins were considered negative.
The date of disease recurrence was defined by the date of pathologic diagnosis or positron emission tomography imaging if pathology was unavailable. Diagnostic methods of disease recurrence were categorized as clinical examination (at a scheduled appointment), patient symptoms (prompting clinical evaluation), or imaging studies (surveillance studies in the absence of an abnormal examination or symptoms). Anatomic site distribution of distant metastases at first and later recurrences was determined. Time to disease recurrence was defined from the date of the primary diagnosis to the date of first disease recurrence diagnosis.
OS after diagnosis of first disease recurrence was the primary outcome. Additional survival data were also obtained from public social security records for patients for whom the last date of follow-up was before July 2013. Survival analysis was restricted to patients who received treatment for disease recurrence.
Statistical Analysis
Statistical analysis was performed using StataIC12 software (StataCorp LP, College Station, Tex). Chi-square tests were used for categorical data and Wilcoxon rank sum tests were used for comparison of medians. Time to disease recurrence and survival were estimated by the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate survival analyses were performed with Cox proportional hazards regression models. Two-sided P values <.05 were considered to be statistically significant. Parsimonious variable selection for the multivariate Cox model was based on clinical and univariate significance. Nonsignificant variables that changed hazard ratios (HRs) by >10% when removed from the model were also retained. 20 
RESULTS
Patient Characteristics
A total of 108 patients met study criteria (Table 1) . The majority of patients were HPV-positive (80 patients; 74.1%). HPV-positive patients were more likely to be white (P<.01), male (P<.01), and never-smokers (P 5 .06) compared with HPV-negative patients. HPVpositive patients were also more likely to have received nonsurgical primary treatment (83.8% vs 53.6%; P<.01).
Patterns of Disease Recurrence
Patterns of disease recurrence were compared by HPV tumor status. HPV tumor status for recurrent disease was available for 45 of 78 HPV-positive patients (57.7%) recurrences. There was no difference in the distribution of disease recurrence (local, locoregional, or distant) by HPV tumor status ( Among patients with any history of distant metastases (57 patients), the lung was the most common site for both HPV-positive and HPV-negative patients (P 5 .18) ( Table 2 ). Mediastinal lymph nodes were the second most common site of distant disease recurrence, followed by bone and skin. The distribution of distant metastatic sites did not differ by HPV tumor status (P 5 .41).
Treatment of Disease Recurrence
The majority of patients received treatment at the time of initial disease recurrence (Table 3) . Surgical salvage was the most common treatment (61 patients; 61.6%) and frequently administered with adjuvant radiation (42 patients; 68.9%). Nonsurgical treatment (33 patients) consisted of chemotherapy (45.5%), radiotherapy (24.2%), and chemoradiation (30.3%), and did not differ by HPV tumor status (Table 3) .
Patients receiving surgical salvage did not differ with regard to age (median age of 56 years vs 58 years; P 5 .28) or primary treatment modality (P 5 .64). However, a greater percentage of patients who underwent surgical salvage were free of disease for 1 year compared with patients who received nonsurgical treatment (75.4% vs 54.5%; P 5 .038). For patients with distant metastatic disease recurrence (38 patients), surgical salvage was also associated with a longer disease-free interval (P 5 .016). Patients with multiple sites of disease were more likely to receive nonsurgical treatment compared with patients with a single disease site (80.0% vs 29.8%; P 5 .002).
Details of surgical procedures were available for all 61 patients who underwent surgical salvage for locoregional or Surgical salvage for distant metastasis was performed for 16 patients, 14 of whom were HPV-positive. These procedures were predominantly pulmonary resections (9 of 16 patients; 56.3%), 7 of which (77.8%) were videoassisted thoracoscopic surgeries and 3 of which (33.3%) were for multiple lung nodules. Four patients underwent mediastinal lymphadenectomy, including 3 with concomitant pulmonary resections. Additional procedures included craniotomy, dermal excision, hepatectomy, and laminectomy. The average length of stay was 3.8 days (11 patients; range, 1-9 days).
Time to Disease Recurrence
Diagnosis of disease recurrence was significantly later for HPV-positive patients than HPV-negative patients (median time to disease recurrence, 19.6 months vs 9.9 months; P<.001) (Fig. 1) . In Kaplan-Meier analysis, HPV-positive patients were found to have an increased time to disease recurrence for both locoregional (P 5 . A majority of recurrences occurred within 2 years after the primary diagnosis for both HPV-positive patients (66.0%; 95% CI, 55.4%-76.3%) and HPV-negative patients (89.3%; 95% CI, 74.9%-97.3%). The method of diagnosis of disease recurrence differed by HPV tumor status (P 5 .02). HPV-positive recurrences were primarily diagnosed by imaging (47.4%), whereas clinical examination was the main method of diagnosis for HPV-negative recurrences (46.4%). Distant metastatic disease was more likely than locoregional disease to be diagnosed by imaging (73.7% vs 24.2%; P<.001). The method of diagnosis was not associated with the time to disease recurrence (P 5 .46).
Survival Analysis
The median follow-up time after disease recurrence was 15.8 months (range, 0.2-105.8 months). HPV-positive patients had significantly improved OS after recurrence compared with HPV-negative patients (3-year OS 55.7% vs 25.2%; P 5 .01) (Fig. 2A) . Median survival was longer for HPV-positive patients compared with HPV-negative patients (82.6 months vs 23.1 months).
Factors associated with OS after disease recurrence on univariate analysis included time to recurrence (1 (Fig. 2B) . The median survival time was 101.5 months for patients who underwent salvage surgery and 14.7 months for those who received nonsurgical treatment.
Patients with locoregional disease recurrence who were treated with surgical salvage had a nonsignificant improvement in survival compared with those who received nonsurgical treatment (P 5 .19) (Fig. 2C) . However, surgical salvage was associated with improved survival in patients with distant metastatic recurrence (P 5 .001) (Fig. 2D ). The median survival for patients with distant metastatic disease who underwent surgical salvage was 35.7 months compared with 12.5 months for patients who received nonsurgical treatment.
Surgical salvage improved OS for both HPVpositive patients (P 5 .03) (Fig. 2E) and HPV-negative patients (P 5 .003) (Fig. 2F ) compared with nonsurgical treatment. For patients with distant metastatic recurrence, surgical salvage was associated with improved OS for both HPV-positive patients (P 5 .03) and HPV-negative patients (P 5 .05), although the number of HPV-negative patients in this group was limited (11 patients).
In multivariate analysis, HPV-positive tumor status (aHR, 0.23; P 5 .002), longer time to disease recurrence (1 year; aHR, 0.36; P 5 .006), primary surgical treatment (aHR, 0.21; P 5 .007), and treatment with surgical salvage (aHR, 0.26; P 5 .002) were each independently associated with improved OS (Table 4) . When patients were stratified by type of disease recurrence, surgical salvage was found to be independently associated with improved survival for both locoregional (aHR, 0.15; 95% CI, 0.04-0.56 [P 5 .005]) and distant (aHR, 0.19; 95% CI, 0.05-0.75 [P 5 .018]) metastatic disease recurrence.
DISCUSSION
The results of this study suggest a robust survival advantage associated with surgical salvage for patients with recurrent OPSCC, even for those with distant metastatic disease. Until recently, 12 recurrent OPSCC was associated with poor OS, and the role of salvage surgery, especially among patients with distant metastatic disease, was questioned within the context of this relatively poor OS and high potential morbidity. [21] [22] [23] Previous studies on surgical salvage of recurrent OPSCC focused primarily on locoregional disease recurrence and did not account for HPV tumor status. 22, [24] [25] [26] In this analysis, OS was evaluated after locoregional and distant metastatic recurrence within the context of HPV tumor status and salvage therapy.
Surgical salvage therapy for the oropharynx has traditionally been associated with increased morbidity such as gastrostomy tube dependence 27 and the need for a midline mandibulotomy. However, the landscape of recurrent OPSCC is changing with the rise of HPV-related disease, 1,2 as well as advancements in surgical approaches to the oropharynx. Transoral robotic surgery has become a viable option for select patients with recurrent OPSCC, with decreased reported morbidity including shorter hospital stays, improved margin control, and decreased tracheostomies and gastrostomy tubes. 28 Based on the extent of recurrent disease, minimally invasive surgery for locoregional disease may not always be possible. It was not used in the majority of locoregional recurrences reviewed herein (4 patients), and thus improvement in OS associated with salvage surgery was likely not dependent on minimally invasive techniques.
Salvage surgery for distant metastatic disease extended the median OS from 12.5 months to 35 months. This reduction in the risk of death remained significant after adjustment for HPV tumor status, age, time to disease recurrence, and multiple sites of disease recurrence (aHR, 0.19; P 5 .018). Surgery for metastatic disease was primarily performed for patients with lung metastases. As observed in this study cohort, minimally invasive pulmonary procedures are also now widely available. 29 An important consideration that was not captured by the current analysis is the quality of life after salvage surgery for distant metastatic disease.
Surgery for metastatic disease poses a departure from the traditional management of metastatic disease in patients with head and neck cancer. Only the chemotherapeutic treatment of distant metastases is supported by strong level 1 evidence within the current National Comprehensive Cancer Network (NCCN) guidelines. 30 Although surgical salvage for distant metastases is an option for patients with good performance status and limited distant disease, evidence for nonchemotherapy treatments are based on lower-level 2A evidence and data defining surgically appropriate distant metastases are lacking. 30 In cancers occurring in other anatomic sites such as the colorectum, NCCN guidelines have integrated sitespecific recommendations for the surgical resection of liver and pulmonary metastases based on an established body of evidence. [31] [32] [33] [34] [35] Nonsurgical approaches for the localized treatment of metastatic disease (eg, radiosurgery) are frequently used for distant metastases and also warrant further investigation. The current study results in the context of current guidelines underscore the need to prospectively collect analogous surgical and nonsurgical salvage data to elucidate the potential role of surgery and radiotherapy in the treatment of patients with distant metastatic OPSCC to inform future guidelines.
Surgical salvage was associated with improved survival for patients with both HPV-positive and HPVnegative disease, although this survival advantage was more prominent in those with HPV-negative disease. Patients with HPV-positive disease recurrence may be more responsive to salvage chemotherapy treatments, 14 thereby attenuating the survival advantage of surgical salvage. To our knowledge, few studies to date have characterized the impact of HPV tumor status on recurrent OPSCC. 13, 14, 36 The data from the current study are consistent with recent observations that HPV-positive patients who develop disease recurrence retain an HPVpositive clinical phenotype including race and smoking history, and do not resemble HPV-negative patients. 12 In concordance with recent literature, anatomic site distribution of disease recurrences did not differ by HPV tumor status. 12 In this cohort, HPV-positive tumor status was associated with a longer time to disease recurrence. These data are consistent with previous reports that the majority of failures, regardless of HPV tumor status, occur within 2 years. 12, 37 Differences in time to disease recurrence may be explained by frequent posttreatment imaging in clinical trial protocols, which could expedite the diagnosis of HPV-positive recurrences. By contrast, fewer than onehalf of recurrences (43%) in this study cohort were diagnosed with imaging studies, the majority of which were HPV-positive (80.4%). It is interesting to note that a longer time to disease recurrence was found to be independently associated with a significant reduction in the risk of death. To the best of our knowledge, this finding has not been reported previously within the context of HPV tumor status. 27 Further studies will elucidate the role of HPV tumor status on the timing of disease recurrence and its implications with regard to the intensity of posttreatment surveillance in the clinical practice setting.
A limitation of the current study is that HPV tumor status was classified based upon tumor status of primary disease rather than disease recurrence. A majority of HPV-positive patients (45 of 78 patients; 57.7%) had HPV tumor status available for disease recurrence. However, previous studies have shown that among patients with prior HPV-positive OPSCC, recurrent disease is HPV-positive in 92% to 97% of cases, including pulmonary recurrences. 18, 19 The primary limitations of the current study are biases inherent to retrospective analyses. In particular, there are potential selection biases that remain unaccounted for, including patient and physician preferences, comorbidities, performance status, and extent of recurrent disease. A prospective study would be necessary to ascertain the rationale for treatment choices and patient eligibility or ineligibility for treatment. Furthermore, the complications and morbidity associated with these treatments could be reliably characterized with prospective data collection. Additional biases may include tertiary institutional referral patterns and nonuniform clinical practices both at the time of primary diagnosis and at disease recurrence. Future prospective studies of the surgical treatment of patients with recurrent and distant metastatic OPSCC will elucidate these relevant clinical questions.
Patients with recurrent OPSCC should be counseled regarding the potential survival advantages of surgical salvage, regardless of HPV tumor status or site of disease recurrence (locoregional or distant). HPV tumor status remains an important prognostic marker in the setting of disease recurrence. These data argue for the inclusion of HPV tumor status and receipt of surgical salvage in the design and analyses of clinical trials. The independent survival advantage of surgical salvage in patients with distant metastatic disease highlights the need to prospectively collect data to inform future NCCN guidelines with higher levels of evidence than currently available.
